Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. ADR (NQ: CLLS )

2.250 -0.150 (-6.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. ADR

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for... 
Via Benzinga
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
Via Benzinga
Recap: Cellectis Q4 Earnings
Cellectis (NASDAQ:CLLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cellectis... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut
Via Benzinga
Cellectis Reveals Preclinical Data On First Allogeneic Dual CAR T-Cell Product In Non-Hodgkin Lymphoma
Via Benzinga
A Preview Of Cellectis's Earnings
Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
30 Stocks Moving In Tuesday's Mid-Day Session
Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year.... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
FDA Lifts Clinical Hold On Allogene's CAR-T Trials
The FDA has lifted the hold on Cellectis SA's (NASDAQ: CLLS) licensed partner, Allogene Therapeutics Inc (NASDAQ: ALLO) clinical trials. The... 
Via Benzinga
21 Stocks Moving in Tuesday's Pre-Market Session
Gainers OneSmart International Education Group Limited (NYSE: ONE) rose 39.1% to $0.2701 in pre-market trading. OneSmart International Education Group received notification from... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
Upgrades For Canada Goose Holdings Inc (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BioRestorative Therapies (NASDAQ:BRTX... 
Via Benzinga
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China
Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The... 
Via Benzinga
Cellectis SA (CLLS) Q3 2021 Earnings Call Transcript
CLLS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
44 Biggest Movers From Yesterday
Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. (NASDAQ: GRVI) gained 39.3% to close at $6.98 after... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
15 Stocks Moving in Monday's Pre-Market Session
Gainers Trevi Therapeutics, Inc. (NASDAQ: TRVI) rose 32.5% to $1.59 in pre-market trading after the company filed Friday to withdraw its offering of shares. Nutriband Inc. (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.